NEW YORK and MAINZ, GERMANY, February 12, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors unanimously approved the termination of the Company’s shareholder rights agreement, commonly referred to as a “poison pill”, which was originally scheduled to expire on August 15, 2021. The shareholder rights agreement was amended to accelerate the expiration date to February 11, 2021, effectively terminating the plan as of that date.
Originally posted here:
Vericel Announces Termination of Shareholder Rights Agreement
JERSEY, Channel Islands, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18.
The rest is here:
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its 2020 Fourth Quarter and Full-year Earnings Conference Call on Friday, February 26, 2021 at 8:30 a.m. EST. Cronos Group’s senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.
Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET Conference Call and Webcast Scheduled for February 18, 2021, 4:30 pm ET
Original post:
Oyster Point Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 18, 2021
AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.
View post:
Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,000 units (“Units”) at a price of $0.50 per Unit for aggregate gross proceeds of $23,000,000 (the “Offering”), which includes the exercise in full of the 15% over-allotment option. The syndicate of underwriters was led by Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (together, the "Underwriters"). The Units were offered and sold by way of a short form prospectus filed with the securities commissions in each of the provinces of Canada, other than Québec.
See the original post here:
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
Delisting of AS „Grindeks” shares from the Baltic Main list
Go here to see the original:
Delisting of AS „Grindeks” shares from the Baltic Main list
Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Continued here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021
NEW YORK, NY , Feb. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as an ongoing Pharmaceutical Development initiative, today announced that it has commenced development of its 1st full spectrum Cannabidiol (“CBD”) infused edibles product line. The Company plans to develop this above referenced product line, with the following attributes: Kosher Certified, Halal Certified, Vegan Formulation, Dairy-Free, Infused with Full Spectrum Hemp Extract (“Full Spectrum”), All-Natural Flavors, Sugar Free/Diabetic Friendly Version(s), and Full Adherence to U.S. Federal Laws & Regulations. The Company expects to provide concrete details about this proposed full spectrum product line within the near term.
See the original post here:
Tauriga Sciences Inc. to Commence Development of its 1st Full Spectrum CBD Infused Edibles Product Line
In addition to preservation of neurocognitive development with ABO-102 in MPS IIIA, new clinical results of ABO-102 in MPS IIIA and ABO-101 in MPS IIIB continue to show dose-dependent and sustained reductions in disease-specific biomarkers, denoting clear biologic effects
BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues to be made, across the following areas.
More here:
Radius Health, Inc. Provides Abaloparatide Business Update
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use
Here is the original post:
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the...
Continue reading here:
Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium...
Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.
Here is the original post:
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
See the original post:
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
See the rest here:
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
Here is the original post:
Neck Hammock Reviews – Does this gadget really help? – Product Review by Mike Vaughn
Nanotechnology in Medical Applications: The Global Market
This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.
Also Read:https://telegra.ph/Global-Dancewear-Market-Statistics-Development-and-Growth-2025-02-02
Report Includes:
An overview of the global markets for nanotechnology used in medical applications
Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications
Also Read: https://techsite.io/p/1944999
Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness
A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine
Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities
Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive marketSummary
Also Read:https://wiseguyreports12.blogspot.com/2021/02/global-china-digital-audio-broadcasting.html
Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.
The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.
Reasons for Doing the Study
Also Read:https://penzu.com/p/240d32a5
Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.ABLYNX NV
ABRAXIS BIOSCIENCE (CELGENE)
APHIOS CORP.
BIOFORCE NANOSCIENCES HOLDINGS INC.
BIO-GATEAG
CALANDO PHARMACEUTICALS INC.
C SIXTY INC. (ARROWHEAD PHARMACEUTICALS)
ELAN (ALKERMES CORP.)
FARFIELD SCIENTIFIC (BIOLIN SCIENTIFIC AB)
IGI LABORATORIES (TELIGENT INC.)
KEREOS INC.
KEYSTONE NANO INC.
KLEINDIEK NANOTECHNIKGMBH
LABOPHARM (PALADIN LABS)
LIPLASOME PHARMA APS
MAGFORCE NANOTECHNOLOGIES
MAGNAMEDICS GMBH
MICROFLUIDICS CORP.
MOLECULAR PROFILES (JUNIPER PHARMA SERVICES)
NANOBIO CORP.
NANOBIOTIX
NANOCARRIER CO. LTD
NANOCOPOEIA, INC.
NANOCYTE INC.
NANOLOGIX INC.
NANOMED PHARMACEUTICALSINC.
NANOMIX INC.
NANOPHARM AG
NANOSPECTRA BIOSCIENCESINC.
NANOSPHERE INC. (LUMINEX CORP.)
NANOSTRUCTURES INC.
NANOSYN INC.
NANOTHERAPEUTICS INC.
NANOTROPE INC.
NANOVIRICIDES INC
NUCRYST PHARMACEUTICALS
NUTRALEASE
ORTHOVITA INC. (STRYKER CORP.)
PIONEER SURGICAL TECHNOLOGY (RTI SURGICAL)
PSIVIDA LTD.
SOLUBEST LTD
STARPHARMA
TECANGROUP LTD.
TRANSGENEX NANOBIOTECH INC.
FOR MORE DETAILS :https://www.wiseguyreports.com/reports/5545026-global-plastic-and-competitive-pipe-market-insights-and-forecast-to-2016
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
[emailprotected]
Ph: +162-825-80070 (US)
Ph: +44 2035002763 (UK)
Here is the original post:
Global NANOTECHNOLOGY IN MEDICAL APPLICATIONS Statistics, CAGR, Outlook, and Covid-19 Impact 2016 The Bisouv Network - The Bisouv Network
TheNanotechnology in Medical market outlooklooks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope and application of this report.
The report presents the market competitive landscape and a corresponding detailed analysis of the majorvendor/key playersin the market.Top Companiesin the Global Nanotechnology in Medical Market:Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune, Access, Camurus, Roche, Dentsply International, 3M, Celgene, Pfizer.
SPECIAL OFFER (Avail an Up-to 25% discount on this report, please fill the form and mention the code: MIR25 in the comments section)
Click the link to get a free Sample Copy of the Report@:
This report segments the global Nanotechnology in Medical market on the basis ofTypesare:
Nano Medicine
Nano Diagnosis
Other
On the basis ofApplication, the Global Nanotechnology in Medical market is segmented into:
Hospitals
Clinics
Others
Investigator Observers Strong Growth in Specific Regions:
EuropeMarket (Germany, UK, France, Russia, Italy)
Center East and AfricaMarket (Saudi Arabia, UAE, Egypt, Nigeria, South Africa)
South AmericaMarket (Brazil, Argentina, Colombia)
North AmericaMarket (United States, Canada, Mexico)
Asia PacificMarket (China, Japan, Korea, India, Southeast Asia).
Inquire For Discount at:
Influence of the Nanotechnology in Medical market report:
-Comprehensive assessment of all opportunities and risk in the Nanotechnology in Medical market.
-Nanotechnology in Medical market recent innovations and major events
-Detailed study of business strategies for growth of the Nanotechnology in Medical market-leading players.
-Conclusive study about the growth plot of Nanotechnology in Medical market for forthcoming years.
-In-depth understanding of Nanotechnology in Medical market-particular drivers, constraints and major micro markets.
-Favorable impression inside vital technological and market latest trends striking the Nanotechnology in Medical market.
Important Features that are under Offering and Key Highlights of the Reports:
Detailed overview of Market
Changing market dynamics of the industry
In-depth market segmentation by Type, Application etc.
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape of Market
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth.
Finally, the Nanotechnology in Medical Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and market development rate and figure, and so on. Nanotechnology in Medical Industry report additionally Presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.
We also offer customization on reports based on specific client requirement:
1-Freecountry level analysis forany 5 countriesof your choice
2-FreeCompetitive analysis ofany 5 key market players.
3-Free40 analyst hoursto cover any other data points.
About Us:
MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReportsprovides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
MediaContact Us:
Irfan Tamboli (Head of Sales) Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com
See the article here:
Nanotechnology in Medical Market Demand Analysis To 2026 Lead By-Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune KSU | The...